¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"receptor amblyopia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® receptor ÇÑ±Û ¼ö¿ëü
¼³¸í   
  ¼¼Æ÷Áú³» ¶Ç´Â ¼¼Æ÷Ç¥¸é¿¡ Á¸ÀçÇϴ ºÐÀÚ±¸Á¶·Î¼­ Æ¯À̹°Áú°ú ¼±ÅÃÀûÀ¸·Î °áÇÕÇϸ砰áÇÕ¿¡ ÀÇÇØ Æ¯ÀÌÇÑ »ý¸®Àû ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. ÆéƼµåÈ£¸£¸ó, ½Å°æÀü´Þ¹°Áú, Ç׿ø, º¸Ã¼, ¸é¿ª±Û·ÎºÒ¸°¿¡ ´ëÇÑ ¼¼Æ÷Ç¥¸é ¼ö¿ëü¿Í ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ¼¼Æ÷Áú³» ¼ö¿ëü°¡ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • anisometropic amblyopia
    ±¼ÀýºÎµî¾à½Ã
  • amblyopia
    ¾à½Ã
  • amblyopia ex anopsia
    Æó¿ë¾à½Ã
  • ametropic amblyopia
    ±¼ÀýÀÌ»ó¾à½Ã
  • binocular amblyopia
    ¾ç¾È¾à½Ã, µÎ´«¾à½Ã
  • color amblyopia
    »ö¾à
  • functional amblyopia
    ±â´ÉÀÌ»ó¾à½Ã
  • hysterical amblyopia
    È÷½ºÅ׸®¾à½Ã
  • meridional amblyopia
    ³¯ÁÙ¾à½Ã, °æ¼±¾à½Ã
  • nocturnal amblyopia
    ¾ß°£¾à½Ã
  • nutritional amblyopia
    ¿µ¾ç°áÇ̾à½Ã
  • organic amblyopia
    ±âÁú¾à½Ã
  • occlusion amblyopia
    °¡¸²¿øÀξà½Ã
  • strabismic amblyopia
    »ç½Ã¾à½Ã
  • suppression amblyopia
    ¾ïÁ¦¾à½Ã
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amblyopia
    ¾à½Ã
  • anisometropic amblyopia
    ±¼ÀýºÎµî¾à½Ã
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • sensory receptor
    °¨°¢¼ö¿ëü
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amblyopia
    ¾à½Ã
  • amblyopia ex anopsia
    Æó¿ë¾à½Ã
  • ametropic amblyopia
    ±¼ÀýÀÌ»ó¾à½Ã
  • anisometropic amblyopia
    ±¼ÀýºÎµî¾à½Ã
  • binocular amblyopia
    ¾ç¾È¾à½Ã, µÎ´«¾à½Ã
  • color amblyopia
    »ö¾à
  • functional amblyopia
    ±â´ÉÀÌ»ó¾à½Ã
  • hysterical amblyopia
    È÷½ºÅ׸®¾à½Ã
  • meridional amblyopia
    ³¯ÁÙ¾à½Ã, °æ¼±¾à½Ã
  • nocturnal amblyopia
    ¾ß°£¾à½Ã
  • nutritional amblyopia
    ¿µ¾ç°áÇ̾à½Ã
  • occlusion amblyopia
    °¡¸²¿øÀξà½Ã
  • organic amblyopia
    ±âÁú¾à½Ã
  • stimulus-deprivation amblyopia
    ÀÚ±ØÂ÷´Ü¾à½Ã
  • strabismic amblyopia
    »ç½Ã¾à½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • receptor amblyopia
    ¼ö¿ë±â¾à½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amblyopia<³ª>
    ¾à½Ã(å°ãÊ).
  • ametropic amblyopia
    ±¼ÀýÀÌ»ó¾à½Ã
  • anisometrpic amblyopia
    ±¼ÀýºÎµî¾à½Ã
  • functional amblyopia
    ±â´É¾à½Ã
  • hysteric amblyopia
    È÷½ºÅ׸®¼º ¾à½Ã
  • hysterical amblyopia
    È÷½ºÅ׸®¾à½Ã
  • quinine amblyopia
    Ű´Ï³×¾à½Ã(¡­å°ãÊ).
  • A1 receptor
    A1 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • A2 receptor
    A2 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • CR1 => complement receptor 1
    º¸Ã¼¼ö¿ëü 1
  • CR2 => complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • CR3 => complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • CR4 => complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • Gustatory receptor
    ¹Ì°¢¼ö¿ëü(Ú«ÊÆâ¥é»ô÷)
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • receptor amblyopia
    ¼ö¿ë±â¾à½Ã
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alcohol amblyopia
    ¾ËÄڿþà½Ã(¡­å°ãÊ).
  • amblyopia
    ¾à½Ã(å°ãÊ)
  • amblyopia ex anopsia<³ª>
    Æó¿ë¾à½Ã(øÈéÄå°ãÊ).
  • amblyopia of abeyance
    ½Ã°¢¹ß´ÞÁßÁö¾à½Ã
  • amblyopia of arrest
    ½Ã°¢¹ß´ÞÁßÁö¾à½Ã
  • amblyopia of disuse
    Æó¿ë¾à½Ã
  • amblyopia of early arrest
    Á¶±âÁ¤Áö¾à½Ã
  • amblyopia of extinction
    ½Ã°¢¼Ò¸ê¾à½Ã
  • amblyopia<³ª>
    ¾à½Ã(å°ãÊ).
  • ametropic amblyopia
    ±¼ÀýÀÌ»ó¾à½Ã
  • anisometrpic amblyopia
    ±¼ÀýºÎµî¾à½Ã
  • binocular amblyopia
    µÎ´«¾à½Ã, ¾ç¾È¾à½Ã
  • color amblyopia
    »ö¾à(ßäå°).
  • deprivation amblyopia
    (½Ã)ÀÚ±ØÂ÷´Ü¾à½Ã
  • functional amblyopia
    ±â´É¾à½Ã
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Receptor
    ¼ö¿ë±â
    [¿¾ ¿ë¾î] ¼ö¿ë±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta receptor
    º£Å¸ ¼ö¿ëü(áôé»ô÷)
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
  • Fc receptor
    Fc ¼ö¿ëü(áôé»ô÷)
  • floating receptor model
    ºÎÀ¯ ¼ö¿ëü(Ý©ë´áôé»ô÷) ¸ðµ¨
  • glucocorticoid receptor
    ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • H1 receptor
    H1 ¼ö¿ëü(áôé»ô÷)
  • H2 receptor
    H2 ¼ö¿ëü(áôé»ô÷)
  • LDL receptor
    LDL ¼ö¿ëü(áôé»ô÷)
  • ligand-receptor internalization
    ¸®°£µå-¼ö¿ëü(áôé»ô÷) ³»ÀÔ(Ò®ìý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • receptor
    ¼ö¿ë±â, ¼ö¿ëü, °¨¼öü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
RAR rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
DR degeneration reaction; delivery room; deoxyribose; diabetic retinopathy; diagnostic radiology; digit...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CRLR Calcitonin Receptor-Like Receptor
EGF-receptor Epidermal Growth Factor receptor
IRR Insulin receptor- related receptor
alpha 2MR/LRP alpha (2)-macroglobulin receptor/low density lipoprotein receptor-related protein
ORL1 opioid receptor like receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • amblyopia
    ¾à½Ã, ½Ã¾à
    °ËÃâÇÒ ¼ö ÀÖ´Â ´«ÀÇ Á¶Á÷Àû ¼Õ»óÀÌ ¾ø´Â ½Ã·ÂÀå¾Ö. ´«¿¡ ±âÁúÀû º´º¯ÀÌ ¾ø´Â ½Ã°¢Àå¾Ö.
  • amblyopia of arrest
    ½Ã°¢ ¹ß´Þ ÁßÁö ¾à½Ã
  • amblyopia of early arrest
    Á¶±â Á¤Áö ¾à½Ã
  • ametropic amblyopia
    ±¼Àý ÀÌ»ó ¾à½Ã
  • anisometrpic amblyopia
    ±¼Àý ºÎµî ¾à½Ã
  • deprivation amblyopia
    ½ÃÀÚ±Ø Â÷´Ü ¾à½Ã
  • functional amblyopia
    ±â´É ¾à½Ã
  • microtropic amblyopia
    ¹Ì¼¼ »ç½Ã ¾à½Ã
  • nocturnal amblyopia
    ¾ß°£ ¾à½Ã
  • occlusion amblyopia
    °¡¸² ¾à½Ã
  • quinine amblyopia
    Ű´Ï³× ¾à½Ã
  • stimulus-deprivation amblyopia
    ½ÃÀÚ±Ø Â÷´Ü ¾à½Ã
  • strabismic amblyopia
    »ç½Ã ¾à½Ã
  • suppression amblyopia
    ¾ïÁ¦ ¾à½Ã
  • tobacco amblyopia
    ´ã¹è Áßµ¶ ¾à½Ã
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
amblyopia <ophthalmology> The impairment of vision without detectable organic lesion of the eye.
(18 Nov 1997)
amblyopia ex anopsia The suppression of the central vision in one eye when the images from the two eyes are so different that they cannot be fused into one. This may be due to: 1) faulty image formation (sensory amblyopia); 2) a large difference in refraction between the two eyes (anisometropic amblyopia); or 3) the two eyes pointing in different directions (strabismic amblyopia). Most suppression amblyopia can be reversed if appropriately treated before age 6 years.
Synonym: amblyopia ex anopsia.
(05 Mar 2000)
anisometropic amblyopia A suppression of central vision due to an unequal refractive error (anisometropia) of at least two diopters. This induces a sufficient difference in image size (aniseikonia) that the two images cannot be fused. In order to avoid confusion, the blurrier image is suppressed.
Synonym: refractive amblyopia.
(05 Mar 2000)
refractive amblyopia A suppression of central vision due to an unequal refractive error (anisometropia) of at least two diopters. This induces a sufficient difference in image size (aniseikonia) that the two images cannot be fused. In order to avoid confusion, the blurrier image is suppressed.
Synonym: refractive amblyopia.
(05 Mar 2000)
sensory amblyopia A suppression of central vision in one eye due to faulty image formation; for example, by a corneal scar, a cataract, or a droopy eyelid.
Synonym: deprivation amblyopia.
(05 Mar 2000)
hysterical amblyopia An apparent loss of visual acuity or visual field with no substantiating physical signs; often due to a natural concern about visual loss combined with suggestibility and a fear of the worst; best treated with reassurance.
(05 Mar 2000)
strabismic amblyopia A suppression of central vision due to the two eyes pointing in different directions. The two scenes cannot be fused into a single image, so, to avoid confusion, one of the images is suppressed.
(05 Mar 2000)
nocturnal amblyopia Night blindness or difficulty in seeing at night. Symptom of vitamin A deficiency.
(27 Sep 1997)
nutritional amblyopia Amblyopia resulting from lack of vitamin B-complex constituents.
(05 Mar 2000)
suppression amblyopia The suppression of the central vision in one eye when the images from the two eyes are so different that they cannot be fused into one. This may be due to: 1) faulty image formation (sensory amblyopia); 2) a large difference in refraction between the two eyes (anisometropic amblyopia); or 3) the two eyes pointing in different directions (strabismic amblyopia). Most suppression amblyopia can be reversed if appropriately treated before age 6 years.
Synonym: amblyopia ex anopsia.
(05 Mar 2000)
deprivation amblyopia A suppression of central vision in one eye due to faulty image formation; for example, by a corneal scar, a cataract, or a droopy eyelid.
Synonym: deprivation amblyopia.
(05 Mar 2000)
toxic amblyopia Blindness due to optic neuritis caused by methyl alcohol, lead, arsenic, quinine, or other poisons.
(05 Mar 2000)
acetylcholine receptor antibodies <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream.
Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission.
Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy.
AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis.
AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis.
Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis.
Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued.
Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears.
(29 Dec 1997)
amino acid receptor <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor.
(18 Nov 1997)
AMPA receptor <cell biology> Glutamate operated ion channel.
See: excitatory amino acid receptor channels.
(05 Feb 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amblyopia
    ¾à½Ã
  • receptor
    ¼ö¿ë±â;°¨°¢±â°ü;¼ö¿ëü
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á